Darolutamide plus androgen deprivation therapy significantly increased overall survival in men with non-metastatic castration-resistant prostate cancer (for specialized target groups only)

Full data to be presented at upcoming scientific meeting
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news